Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Michelle R. Mahoney(Mayo Clinic), Brian Andrew Van Tine(Washington University in St. Louis), James N. Atkins(Southeast Clinical Oncology Research Consortium), Mohammed Milhem(University of Iowa), Balkrishna Jahagirdar(University of Minnesota), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Elise Horvath(University of Chicago), William D. Tap(Cornell University), Gary K. Schwartz(Columbia University), Howard Streicher(National Cancer Institute)
Cited by 743Open Access